Advancing HFpEF Treatment with Novel MRAs - Episode 9
Finerenone Benefits and Anticipated Guideline Updates for HFpEF
Experts discuss the clinical implications of finerenone’s benefits and forecast how upcoming guidelines may shift standard care practices.
Panelists discussed finerenone’s unique benefits for patients with heart failure with preserved ejection fraction, particularly those with metabolic or renal comorbidities. Its anti-inflammatory and antifibrotic properties make it an attractive option for long-term management.
The conversation noted that upcoming guideline updates are expected to reflect the growing body of data supporting nonsteroidal mineralocorticoid receptor antagonists. Such changes may encourage broader use of finerenone in both cardiology and primary care settings.
Experts emphasized that integrating new evidence into everyday practice will require education, access support, and continued postmarket research to refine patient selection and outcomes.
